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Introduction
Myostatin (Mstn) (formerly growth and differentiation factor 8) 
is an endogenous, secreted protein from the transforming 
growth factor-β superfamily that negatively regulates skeletal 
muscle growth and differentiation.1 Mstn null mutations result 
in  increased  musculature  in  cattle,2  mice1,3  and  humans.4 
Mstn inhibition has been shown to induce functional improve-
ment in  the  mdx  mouse  model5–10 of  Duchenne  muscular 
dystrophy, an X-linked, monogenic muscle wasting disorder 
caused by loss-of-function mutations in the gene encoding 
dystrophin. Impaired dystrophin function results in progres-
sive muscle degeneration leading to death, typically in the 
third decade of life by cardiac or respiratory failure.11 Previ-
ous studies have demonstrated that the combination of Mstn 
blockade with dystrophin restoration in mdx mice resulted in a 
greater functional improvement than either treatment alone.12 
Consequently,  the  Mstn  signaling  pathway  is  a  promising 
pharmacological target for the treatment of muscle wasting 
conditions such as Duchenne muscular dystrophy. A num-
ber of strategies have been used to achieve Mstn blockade 
including Mstn neutralizing antibodies,13 endogenous Mstn 
antagonists (Mstn propeptide,5 follistatin,7 and soluble Acvr2b 
(the Mstn receptor)),14 destructive exon-skipping,15 and RNA 
interference (RNAi).16
An alternative to the canonical RNAi pathway (also known as 
post-transcriptional gene silencing, PTGS) is transcriptional 
gene  silencing  (TGS).17,18 TGS  is  a  homology-  dependent 
gene silencing pathway mediated by small interfering RNAs 
(siRNAs),  viral/plasmid  expressed  short  hairpin  RNAs19 
or expressed antisense RNAs20,21 with complementarity to 
  target gene promoters. These small RNA effector molecules 
target  low  copy-number  promoter-associated  RNA  tran-
scripts22 in order to recruit   chromatin-remodeling factors20 
to the complementary promoter and, in some cases, induce 
promoter  DNA  methylation.19,22 The  induction  of  targeted 
epigenetic  changes  enables  long-term  therapeutic  gene 
silencing. To this end Suzuki et al. showed that transient 
transfection of an siRNA targeting the human immunodefi-
ciency virus-1 5′ long terminal repeat was able to suppress 
human immunodeficiency virus replication for 31 days in the 
HeLa-derived MAGIC-5 cells.23 Building on this work, Yama-
gashi et al. were able to silence human immunodeficiency 
virus messenger RNA (mRNA) transcription and viral rep-
lication for up to 1 year using a retrovirus-expressed short 
hairpin RNAs in a T-cell line (Molt-4).24 Similarly, Hawkins 
et al. showed that long-term (up to 31 days) transcriptional 
silencing of Ubiquitin C could be achieved by 3 days of tet-
induced promoter-targeted short hairpin RNAs expression.17 
Collectively, these studies suggest that long-term, targeted 
gene suppression by TGS may be possible in a therapeutic 
context. The aim of this work is to demonstrate the feasibil-
ity of silencing of Mstn expression by TGS. We show that 
Mstn expression is silenced by a promoter-targeted siRNA 
and that the silencing involves epigenetic remodeling of the 
Mstn promoter. This study thus opens up a new therapeutic 
avenue in the treatment of muscle wasting disorders.
Results
Detection of Mstn promoter-associated RNA
Previous studies have shown that TGS in mammalian cells 
requires the presence of promoter RNA transcripts. The data-
base of transcription start sites25 and University of Califor-
nia, Santa Cruz genome browser26 resources were used to 
identify the Mstn transcription start site. To characterize tran-
scription at the Mstn promoter, directional reverse transcrip-
tion  polymerase  chain  reaction  (RT-PCR)  was  performed 
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using primers that amplify a 153 bp region upstream of the 
annotated transcription start site in a strand-specific manner 
(Figure 1a). Transcripts were detected in both sense and 
antisense orientations indicating the presence of promoter-
associated RNA at the Mstn promoter. PCR amplicons were 
sequenced to confirm identity (data not shown). Reverse tran-
scriptase minus (RT−) control PCR reactions failed to amplify 
ruling out genomic DNA contamination (Figure 1b).
Promoter-targeting  siRNAs  induce  transcriptional 
  silencing of Mstn
Four siRNAs targeting the Mstn sense promoter-associated 
RNA  (Figure  1a)  were  synthesized  by  in  vitro  transcrip-
tion, transfected into differentiated C2C12 myotube cultures 
and  Mstn  expression  assessed  by  reverse  transcriptase-
  quantitative PCR (RT-qPCR). A mRNA-targeting siRNA that 
induces post-transcriptional gene silencing of Mstn was used 
as a positive control (PTGS control). One siRNA, siMstn-P2, 
was found to significantly reduce Mstn mRNA levels by 50% 
(Figure 1c). This level of silencing was observed in at least 20 
independent transfections under similar conditions (i.e. 100 
nM siRNA in differentiated myotube cultures) and found to be 
highly reproducible (mean knockdown = 48%, SD = 11.5%).
Reduction in Mstn expression was observed relative to two 
unrelated nonspecific control (NS ctrl) siRNAs (including an 
in vitro transcribed siRNA (siCCR5) which targets the human 
C–C  chemokine  receptor  type  5)  (Supplementary  Figure 
S1a). In addition, transfection with two further control siRNAs; 
one with the siMstn-P2 sequence scrambled (siScrambled) 
and the other with the central four nucleotides of siMstn-P2 
inverted  (siMM),  did  not  significantly  reduce  Mstn  expres-
sion (Supplementary Figure S1b). Negligible batch-to-batch 
variation  was  observed  between  different  siRNA  prepara-
tions (Supplementary Figure S1c) and no significant cellular 
toxicity was observed between any of the siRNA treatments 
(Supplementary Figure S1d). Mstn silencing was further con-
firmed using a chemically synthesized siMstn-P2 (Figure 2a). 
In addition, promoter-targeted silencing was dose-  dependent 
although significant Mstn knockdown was only observed at 
siRNA concentrations of 50 nM and 100 nM (Figure 2b). Con-
versely, maximal silencing by the PTGS control siRNA was 
observed at 10 nM (data not shown). Statistically significant 
knockdown of Mstn was also observed in H2K mdx cells (a 
murine myoblast cell line that carries a mutation in dystrophin 
exon 23)27 indicating that the silencing effect is not restricted 
to the C2C12 line (Figure 2c). Taken together, these data sug-
gest that Mstn is susceptible to siRNA-directed TGS.
Previous studies have suggested that delivery of siRNA to 
the nucleus is essential to induce TGS and that nuclear tar-
geting peptides were required to facilitate this delivery.18,20,28 
However,  in  this  study  silencing  was  observed  with  both 
conventional,  commercially  available  transfection  reagents 
(INTERFERin and RNAiMax) and with a stearylated trans-
portan-10 derived peptide (PepFect14) that had previously 
been shown to effectively deliver splice-switching oligonucle-
otides to the nucleus29 (Figure 2d).
Given that TGS and PTGS occur via different mechanisms, 
we hypothesized that co-transfection of TGS and PTGS siR-
NAs would act in a combinatorial manner to improve maximal 
Mstn gene silencing. Transfection of a combination of 50 nM 
siMstn-P2 and 50 nM PTGS control siRNA was compared 
against 100 nM of each individual siRNA or a NS ctrl siRNA. 
The combination of the two siRNAs gave the greatest knock-
down (87%) (Figure 2e).
Mstn silencing is independent of interferon induction
In contrast with chemically synthesized siRNA molecules, small 
RNAs generated by in vitro transcription from T7 promoters are 
tri-phosphorylated  at  the  5′  terminus  and  therefore  have  the 
potential to induce nonspecific knockdown by activating the inter-
feron response.30 In order to investigate this possibility, C2C12 
myotube cultures were transfected with all relevant siRNAs. After 
48 hours total RNA samples were reverse transcribed and levels 
of the interferon-induced genes 2′,5′ oligoadenylate synthase 
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1b and interleukin-6 were determined by RT-qPCR. Treatment 
with 15 μg/ml lipopolysaccharide was used as a positive control 
for interferon induction. Statistically significant induction of oli-
goadenylate synthase 1b and interleukin-6 was observed with 
the in vitro transcribed siRNAs (siMstn-P2 and siCCR5) but not 
with chemically synthesized siRNAs (Figure 3a,b). The stabil-
ity of the reference gene transcript (β-Actin) was   unaffected by 
transfection with in vitro transcribed siRNAs   (Figure 3c). These 
results indicate that in vitro transcribed Silencer constructed siR-
NAs induce expression of interferon-stimulated genes whereas 
chemically synthesized siRNAs do not.
Epigenetic Mstn silencing
Acetylation of histone H3 lysine residues 9 and 27 is associ-
ated with transcriptionally active chromatin. Consequently, 
deacetylation  of  these  residues  is  a  necessary  first  step 
in the process of silent state chromatin formation. In order 
to determine whether siMstn-P2 induces epigenetic gene 
silencing,  transfections  were  performed  in  the  presence 
of  the  histone  deacetylase  inhibitor  trichostatin  A  (TSA). 
siRNA  transfected  cultures  were  treated  with  a  range  of 
TSA concentrations (50 nM to 5 μM) and for each experi-
mental  condition  Mstn  expression  was  normalized  to  the 
NS ctrl. Silencing by siMstn-P2 was found to be sensitive 
to TSA concentrations above 500 nM whereas silencing by 
the  PTGS  control  siRNA  was  largely  unaffected  (Figure 
4a). Treatment with TSA was found to activate basal Mstn 
expression at low concentrations and was toxic at high con-
centrations, which is consistent with other reports31 (Figure 
4b,c). The observation that Mstn silencing by siMstn-P2 was 
abrogated by treatment with TSA at concentrations that acti-
vate Mstn expression in one case (500 nM) and are highly 
toxic in another (5 μM) is evidence that these factors are not 
confounding the results.
To investigate whether changes in chromatin structure are 
involved in Mstn silencing we performed chromatin immu-
noprecipitation analysis (ChIP) using antibodies against the 
silent state histone modifications; dimethyl-histone H3 lysine9 
(H3K9me2) and trimethyl-histone H3 lysine27 (H3K27me3). 
Enrichment of H3K9me2 was detected at the Mstn promoter 
following  treatment  with  siMstn-P2  although  no  change  in 
H3K27me3 was detected (Figure 4d). Sensitivity of silencing 
to TSA treatment and changes in H3K9 methylation suggest 
that epigenetic remodelling at the Mstn promoter underlies 
the observed silencing effect.
Discussion
Here we have demonstrated that siRNAs complementary to 
the Mstn promoter induce silencing of Mstn mRNA expres-
sion. We have detected promoter-associated RNAs at the 
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Mstn locus and the sense-orientation transcript is the pre-
dicted target for the siRNA (although we have not shown a 
direct association between these two RNA species). Silenc-
ing was abrogated by treatment with the histone deacety-
lase  inhibitor, TSA.  Conversely,  the  PTGS  control  siRNA, 
which silences Mstn by acting upon the mature mRNA, was 
unaffected  by  TSA  treatment.  These  results  suggest  that 
silencing with a promoter-targeting siRNA occurs by a differ-
ent gene silencing pathway from conventional RNA interfer-
ence. The results are consistent with other studies of TGS 
although we have not shown direct evidence of silencing at 
the level of transcription.
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We also observed that the combination of TGS and PTGS 
siRNAs resulted in higher levels of silencing than either strat-
egy alone suggesting that the two silencing pathways can 
operate  in  a  combinatorial  manner.  We  and  others  have 
shown that, following transient transfection of TGS effectors, 
target genes are typically silenced by ~50% which is consid-
erably less than with conventional RNAi. However, the level of 
silencing is expected to increase over time as the chromatin 
at the target locus becomes progressively more compacted 
and the promoter DNA methylated. These silencing kinetics 
were observed in studies that looked at long-term knockdown 
by TGS.17,24,32 However, in the case of Mstn, even relatively 
low levels of silencing (27% protein reduction) have been 
shown to result in significant functional changes in muscle 
mass (10% increase) suggesting that high levels of silencing 
are not required for a therapeutically relevant effect.16 The 
demonstration of protein level silencing will be required to 
advance TGS as a therapy although, in this study, we were 
unable to consistently detect Mstn protein in cultured cells by 
western blot.
Several of the early studies to report TGS in mammalian 
cells used siRNAs produced by in vitro transcription.18,20,28 
siRNAs produced in this manner have the potential to elicit 
off-target  gene  silencing  via  induction  of  the  interferon 
response.30 These nonspecific events are either due to a 
gene being directly regulated by interferons, or as a result 
of  global  mRNA  down-regulation,  following  activation  of 
RNase L. We investigated this phenomenon by measuring 
expression of two interferon-induced genes (2′,5′ oligoad-
enylate  synthase  1b  and  interleukin-6)  following  siRNA 
transfections in order to ensure specific Mstn silencing by 
siMstn-P2. We have shown that in vitro transcribed siRNAs 
induce highly statistically significant increases in expression 
of interferon-stimulated genes. However, the findings that; 
(i) silencing is observed with a synthetic siMstn-P2 in the 
absence of induction of the interferon-stimulated genes, (ii) 
silencing occurs relative to an in vitro transcribed control 
siRNA (siCCR5) and (iii) the stability of the housekeeping 
transcript (β-Actin) is unaffected by transfection with in vitro 
transcribed siRNAs, suggests that Mstn inhibition is not the 
result of off-target silencing because of interferon induction 
and activation of RNase L, but is rather a target-specific 
silencing effect.
Promoter-specific  silencing  was  reversed  in  the  pres-
ence of the histone deacetylase inhibitor, TSA, consistent 
with previous studies that have shown that histone deacety-
lase 1 is required for TGS.17,32 Similarly, we have detected 
a modest enrichment of the silent state chromatin modifica-
tion, H3K9me2, following transfection with a Mstn promoter-
  targeting  siRNA  as  reported  previously.17,20,24,28,32  These 
results  are  indicative  of  an  epigenetic  silencing  process. 
Interestingly,  enrichment  of  H3K27me3  was  not  detected. 
Hawkins et al. have shown by RNAi depletion experiments 
that Enhancer of zeste homologue 2, a histone methyltrans-
ferase that methylates histone H3 lysine27, is not essential 
for TGS. This suggests that epigenetic silencing can occur in 
the absence of H3K27 methylation and that there is a degree 
of redundancy between silent state histone modifications.17
The detection of a promoter transcript involved in epige-
netic  regulation  of  the  Mstn  locus  suggests  that  this  may 
constitute part of an endogenous mechanism of gene regula-
tion. Several studies have identified endogenous small RNAs 
(microRNAs) with complementarity to target gene promoters 
that induce TGS.33–35 Long antisense RNAs have also been 
linked to epigenetic control of gene expression36,37 and have 
been found to bind chromatin-remodeling factors.38 Recently, 
a long noncoding RNA has also been implicated in myogene-
sis by acting as a competitive inhibitor for microRNAs involved 
in muscle differentiation.39 However, the role of long noncod-
ing RNAs, microRNAs, and pRNAs in epigenetic silencing is 
still not well understood.
This study adds to the growing literature that suggests 
small RNAs can direct TGS in mammalian cells and con-
firms that TGS occurs in mouse cells consistent with previ-
ous reports.40 Several studies have demonstrated TGS in the 
absence of epigenetic changes, so-called antigene TGS.41,42 
These studies generally use oligonucleotides targeting tran-
scriptional start sites and are speculated to involve direct 
interaction between the oligonucleotide and chromosomal 
DNA. Our data are more consistent with studies which have 
found  a  role  for  epigenetic  changes  involved  in  silencing 
and therefore lend credence to the idea that there are at 
least  two  distinct TGS  mechanisms  (epigenetic-TGS  and 
antigene-TGS).
The use of TGS in animal models has so far been limited to 
three studies. Turunen et al. demonstrated that TGS of vas-
cular endothelial growth factor is possible in mouse muscle 
following lentiviral transduction.40 Similarly, local injection of 
promoter-targeting siRNAs against the human papilloma-
virus E6/E7 and thioredoxin-interacting protein promoters 
results in TGS in mouse xenograft tumors43 and rat retina,44 
respectively. Although these studies are highly promising, 
the general application of TGS in vivo has not yet been fully 
explored  and  may  present  its  own  unique  obstacles.  For 
instance, the relative abundance of promoter transcripts is 
likely to differ between cell culture models and live animals 
and may affect the efficacy of a TGS approach. Despite the 
paucity of in vivo studies the therapeutic application of TGS 
is a promising alternative to RNAi, which is dependent on 
the presence of RNAi effectors that are gradually degraded 
within the cell or dispersed between daughter cells following 
cell division (effectively halving their concentration). Repeat 
administration is therefore required to elicit long-term silenc-
ing by siRNAs. Conversely, TGS effectors induce long-term 
silencing that is inherited following cell division and main-
tenance of silencing is not dependent on the presence of 
effector  molecules.17  A  single  treatment  (or  short  course 
of treatments) may be sufficient to induce long-term gene 
silencing, hence repeat administration of TGS effectors is 
not required.17,23 Consequently, TGS-based therapies may 
require a small number of high doses to elicit an effect. The 
overall dose will thus be lower with TGS-based therapies 
as opposed to conventional RNAi, meaning lower toxicity of 
treatments and greatly reduced material costs. In addition, 
it has been shown that saturation of endogenous RNA pro-
cessing pathways can lead to acute toxicity in vivo.45 As TGS 
does not require repeat administration this risk is greatly 
reduced. Epigenetic silencing of Mstn by TGS is therefore 
a promising novel therapeutic strategy in the treatment of 
muscle wasting disorders.Molecular Therapy–Nucleic Acids
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Materials and Methods
Directional  RT-PCR. Total  RNA  was  extracted  from  C2C12 
myotubes using TRIzol reagent (Invitrogen, Paisely, UK) as 
according to the manufacturer’s protocol and DNase treated 
using  the  TURBO  DNase-free  kit  (Ambion/Applied  Biosys-
tems, Warrington, UK). 1 μg of total RNA was then reverse 
transcribed using SuperScript III RT (Invitrogen). In order to 
differentiate between sense and antisense transcripts com-
plementary  DNA  (cDNA)  synthesis  was  primed  with  either 
MstnPro-Rev (5′-AGCTTGCCCTCGACTGTAAC) or MstnPro-
Fwd (5′-TCCAAGTGGCTTTTTATATTCCA), respectively. Fol-
lowing reverse transcription, PCR was performed with both 
primers and the amplification products analyzed by agarose 
gel electrophoresis. Mock reverse transcription controls (RT−) 
were performed to demonstrate that product amplification was 
not because of genomic DNA contamination. PCR products 
were gel extracted and sequenced to confirm identity.
siRNA. siRNAs were produced by in vitro transcription using 
the Silencer siRNA construction kit (Ambion) as according to 
manufacturer’s instructions or by chemical synthesis (Euro-
gentec, Seraing, Belgium). Chemically synthesized siRNAs 
had 3′ dTdT overhangs. siRNAs designed to target the Mstn 
sense promoter-associated RNA all conform to the AA(N19) 
pattern. All siRNA sequences used in this study are listed in 
Supplementary Table S1. Unless otherwise stated NS ctrl 
refers to “control siRNA duplex negative control” (Eurogen-
tec, catalogue #SR-CL000-005). In addition, an siRNA which 
targets  human  C–C  chemokine  receptor  type  5  (CCR5) 
mRNA was used as an additional NS ctrl produced by in vitro 
transcription. The sequence of the PTGS control siRNA was 
a kind gift from Luis Garcia.
Cell culture. C2C12 mouse myoblasts were maintained in 
growth  media;  Dulbecco’s  modified  Eagle’s  media  supple-
mented with 15% fetal bovine serum and antibiotic/antimy-
cotic (all Invitrogen) and 5% CO2. For differentiation, 24 well 
cell culture plates were coated with 0.02% gelatin (Sigma-
  Aldrich,  Dorset,  UK)  and  UV  sterilized.  C2C12  myoblasts 
were seeded (5 × 104 cells/ml) in growth medium and grown 
overnight. When confluent, the cells were switched to differ-
entiation media; Dulbecco’s modified Eagle’s media supple-
mented  with  5%  horse  serum  (Invitrogen)  and  antibiotic/
antimycotic. Cells were cultured in differentiation media for 
seven days in order to induce differentiation to myotubes.
H2K  mdx  tsA58  mouse  myoblasts27  were  cultured  in  Dul-
becco’s  modified  Eagle’s  media  supplemented  with  20% 
fetal bovine serum), 2% chick embryo extract (PAA Labora-
tories Ltd, Yeovil, UK) and 20 U/ml γ-interferon (Invitrogen) at 
33 °C and 10% CO2 When confluent, the H2K mdx cells were 
switched to differentiation medium and switched to 37 °C and 
5% CO2 for 7 days.
Cells  were  transfected  with  RNAiMax  (Invitrogen)  and 
INTERFERin (PolyPlus Transfection, Strasbourg, France) were 
performed as according to manufacturer’s instructions. Peptide 
transfections with PepFect 14 (CePep, Stockholm, Sweden) 
were performed as follows. Separate peptide and siRNA solu-
tions were prepared in sterile water. The mixes were combined 
in a ratio of 30:1 (peptide:siRNA), mixed gently and incubated 
for 30 minutes at 37 °C to allow transfection complexes to 
form. After incubation, the transfection mixtures were diluted 
in optiMEM (Invitrogen) to a total volume of 0.45 ml per well 
(24 well plate). The media was removed from the C2C12 cul-
tures  and  the  cells  washed  with  phosphate  buffered  saline 
(Invitrogen). Transfection  complexes  in  optiMEM  were  then 
added to each well as appropriate and the cultures returned 
to the incubator. After 1 hour the cultures were supplemented 
with 50 μl fetal bovine serum and after 24 hours the trans-
fection mixture was removed and replaced with fresh media. 
For all experiments mock transfections received transfection 
reagent/peptide  only.  Trichostatin  A  and  lipopolysaccharide 
(both Sigma-Aldrich) were added to cell culture medium as 
appropriate. Cell viability was determined using the MTS assay 
(Promega, Southampton, UK) as according to manufacturer’s 
instructions.
RT-qPCR.  RT-qPCR was performed as follows. The planning, 
implementation and reporting of RT-qPCR experiments were 
designed to comply with the Minimum Information for publica-
tion of Quantitative real-time PCR Experiments guidelines46,47 
as much as was possible or appropriate. To generate cDNA 
2 μg of high quality total RNA was reverse transcribed using 
the High-Capacity cDNA Synthesis kit (Applied Biosystems) 
as according to manufacturer’s instructions. 20 μl RT reac-
tions were primed using random primers. Samples were incu-
bated at 25 °C for 10 minutes to allow primer extension to 
occur and then cDNA was reverse transcribed for 2 hours at 
37 °C. The reaction was terminated at 80 °C for 15 minutes. 
Typically 200 ng cDNA was added to each reaction such that 
a maximum of 2 μl of RT reaction was added per well. RT-
qPCR was performed on a StepOne Plus Real-Time PCR 
System (Applied Biosystems) using TaqMan Gene Expres-
sion Mastermix (Applied Biosystems). Relative quantities of 
target mRNA were determined using the relative standard 
curve method. Data were analyzed using the StepOne Soft-
ware v2.1 (Applied Biosystems). Standard curves were pro-
duced from serial dilutions of cDNA reverse transcribed from 
untreated experimental samples. Universal cycling conditions 
were used (95°C for 10 minutes (hotstart) and then 40 cycles 
of 95°C for 15 seconds, 60°C for 1 minute). Typically, gene 
of interest expression was normalized to β-Actin expression. 
TaqMan assays were purchased from Applied Biosystems 
and are listed in Supplementary Table S2. Validation of RT-
qPCR assays is described in Supplementary Materials and 
Methods and Supplementary Figures S2 and S3.
ChIP. ChIP was performed as described previously with 
several modifications.17 A full protocol is described in the 
Supplementary Materials and methods. Briefly, C2C12 
myotubes were cultured in 10 cm dishes and siRNAs trans-
fected with RNAiMax. After 48 hours cells were harvested 
for ChIP assays. Chromatin samples were formaldehyde 
cross-linked, sonicated to shear the chromatin DNA and 
histone complexes and immunoprecipiated with antibodies 
against  H3K9me2  (#07-441,  Upstate/Millipore,  Billerica, 
MA)  and  H3K27me3  (#97565,  Cell  Signalling Technolo-
gies, Danvers, MA). DNA was recovered by phenol chloro-
form extraction and resuspended in 30 μl of nuclease free 
water. Quantitative PCR was performed on a Mastercycler 
Realplex real-time thermal cycler (Eppendorf, Hauppauge, www.moleculartherapy.org/mtna
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NY) using KAPA SYBR Fast SYBR mastermix (KAPA Bio-
systems, Cambridge, MA) and the primers; MstnChIP-Fwd 
(5′-AGATTCATTGTGGAGCAGGAG)  and  MstnChIP-Rev 
(5′-ATATTAGTGCATGTACCGTCCG).  The  relative  stan-
dard  curve  method  was  used  to  compare  samples  and 
a five fold dilution of input chromatin DNA used to pre-
pare  the  standard  curve  (Supplementary  Figure  S4a). 
Dissociation curve analysis confirmed that only a single 
amplification  product  was  generated  by  the  PCR  reac-
tion (Supplementary Figure S4b). Sample values were 
calculated as background subtracted, fraction of input for 
each experimental group and then normalized to the NS 
ctrl siRNA group.
Statistical  analysis.  All  statistical  analysis  was  performed  in 
SPSS v11.5 (IBM, Armonk, NY, USA). Data were assessed 
for normalcy using the Shapiro–Wilk test and equality of vari-
ance by the Levene’s test. Significance within a data set was 
determined  by  one-way  ANOVA  (analysis  of  variance)  and 
significant differences between treatment groups were deter-
mined by post hoc analysis. The Bonferroni correction or the 
Games–Howell test were used in the instances of equality and 
inequality of variance respectively. P values less than 0.05 were 
considered significant. Unless otherwise indicated all statistical 
comparisons are made against NS ctrl siRNA treated cultures 
(grey bars).
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